A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
CanariaBio Inc.
AstraZeneca
Genelux Corporation
Qilu Pharmaceutical Co., Ltd.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
Eli Lilly and Company
pharmaand GmbH
Xennials Therapeutics Australia Pty Ltd
AGO Research GmbH
AstraZeneca
Daiichi Sankyo
Critical Outcome Technologies Inc.
MEI Pharma, Inc.
Shenzhen SiBiono GeneTech Co.,Ltd
Sanofi
Eli Lilly and Company